# A Study to Evaluate the Drug-drug Interaction and Safety Between "BR6001-1" and "BR6001-2"

> **NCT06165237** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 30 (actual)

## Conditions studied

- Gastric or Duodenal Ulcer

## Interventions

- **DRUG:** BR6001-1
- **DRUG:** BR6001-2

## Key facts

- **NCT ID:** NCT06165237
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-30
- **Primary completion:** 2023-05-09
- **Final completion:** 2023-05-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06165237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06165237, "A Study to Evaluate the Drug-drug Interaction and Safety Between "BR6001-1" and "BR6001-2"". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06165237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*